Aligos Therapeutics Showcases Innovative Research at HBV Meeting

Aligos Therapeutics Presents Breakthrough Findings at International HBV Meeting

Aligos Therapeutics, Inc. (Nasdaq: ALGS), a highly regarded clinical-stage biopharmaceutical company, has brought attention to its innovative research with the announcement of six significant preclinical presentations scheduled for the International HBV Meeting. This event, focused on hepatic and viral diseases, will showcase compelling topics from September 8 to 12, 2025.

The company’s efforts revolve around enhancing patient care through next-generation therapies. This commitment is manifested in their presentations, which explore novel mechanisms of action, advancements in treatment strategies, and potential cures for viral infections. Notably, researchers will discuss a pioneering antisense oligonucleotide (ASO) approach targeting the hepatitis delta virus (HDV).

Advancements in HBV Treatment Strategies

Aligos is particularly enthusiastic about presenting its findings related to ALG-000184, a product showing promise in reducing HBV cccDNA. "We are excited to share our ongoing Phase 2 B-Supreme study results that underscore the efficacy of ALG-000184 in a preclinical setting. Preliminary data aligns well with clinical observations of reduced HBV antigen levels in treated patients," explained Lawrence Blatt, PhD, MBA, Chairman, President, and CEO of Aligos Therapeutics.

The research not only reaffirms ALG-000184's direct actions on the Hepatitis B virus but also emphasizes its secondary mechanisms that can further benefit patients. Aligos is adamant about the potential this drug has in the fight against chronic HBV infection while also making strides in targeting HDV co-infection, a condition that complicates and accelerates liver disease progression.

Overview of Presentations

Aligos will be presenting a diverse range of papers as part of its commitment to sharing knowledge and advancing research in the field:

• Paper #: 52
  Type: Oral Presentation
  Title: The CAM-E ALG-001075 potently reduces HBV cccDNA in preclinical experiments
  Presenter: Yannick Debing, PhD
  Date/Time: September 11, 2025, 10:30 AM – 12:00 PM CET
  Session: Therapy II
• Paper #: 53
  Type: Oral Presentation
  Title: Antisense oligonucleotide-based strategy to target hepatitis delta virus infections
  Presenter: Julie Lucifora, PhD
  Date/Time: September 11, 2025, 10:30 AM – 12:00 PM CET
  Session: Therapy II
• Paper #: 2
  Type: Oral Presentation
  Title: A Syrian hamster model of persistent HDV infection
  Presenter: Elias Broeckhoven
  Date/Time: September 8, 2025, 5:00 PM – 6:30 PM CET
  Session: Molecular Virology I
• Paper #: 283
  Type: Poster Presentation
  Title: Differential impact of CAM-E and CAM-A on hepatitis B core protein phosphorylation states in vitro
  Presenter: Hannah Vanrusselt
  Date/Time: September 10, 2025, 11:00 AM – 12:00 PM CET
  Session: Poster Session II
• Paper #: 285
  Type: Poster Presentation
  Title: Capsid assembly modulators bind and directly target HBeAg
  Presenter: Jordi Verheyen
  Date/Time: September 10, 2025, 11:00 AM – 12:00 PM CET
  Session: Poster Session II
• Paper #: 127
  Type: Poster Presentation
  Title: PML nuclear bodies store aggregated HBc and reduce CAM-induced apoptosis in HBc-expressing cells
  Presenter: Vaclav Janovec, PhD
  Date/Time: September 8, 2025, 5:00 PM – 6:30 PM CET
  Session: Molecular Virology

Company Overview and Future Directions

Aligos Therapeutics, Inc. stands at the forefront of innovation in biotechnology, driven by a determination to meet the unmet medical needs of patients suffering from liver and viral diseases. With a dedicated pipeline focused on chronic hepatitis B virus (HBV), metabolic dysfunctions such as steatohepatitis, and emerging threats like coronaviruses, Aligos paints a promising picture for the future of therapeutic development.

The company maintains its commitment to pushing forward in its research and is optimistic about the potential impact its discoveries may have on treating these challenging conditions. For ongoing updates and insights, please visit the official Aligos website, which will also host the posters and presentations from the HBV Meeting following the event.

Frequently Asked Questions

What is the focus of Aligos Therapeutics?

Aligos Therapeutics specializes in developing therapies for liver and viral diseases, particularly focusing on conditions like hepatitis B and C.

Where will Aligos present its research findings?

The research will be presented at the International HBV Meeting held from September 8-12, 2025.

What are ALGS’s significant products?

ALGS’s notable product includes ALG-000184, which is showing promise in reducing HBV cccDNA levels.

Are there any strategies targeting hepatitis delta virus?

Yes, Aligos is employing an antisense oligonucleotide strategy to potentially cure hepatitis delta virus infections.

How can investors learn more about Aligos?

Investors can find more information on the Aligos website or through direct contact with their investor relations representatives.

About The Author

Greetings, I'm 32-year-old author and financial specialist Evelyn Baker. My introduction into the financial industry started with an economics degree and continued with a wealth of experience in wealth management and financial consulting. My great passion over the years has been assisting people and companies in making wise, well-informed decisions to reach their financial objectives.

My goal with writing is to simplify difficult financial ideas into understandable, doable guidance. My goal in writing many books and articles is to make personal finance understandable to everyone, irrespective of their experience or background. I want to give readers the information they need to take charge of their financial futures, from investing and retirement planning to budgeting and saving.

Along with my writing, I lead webinars and workshops where I provide doable advice and methods for achieving financial success. To reach a larger audience, I also frequently contribute to financial blogs and publications. My method is always to offer doable, real-world guidance that can actually improve people's lives.

Aside from my job, I like to cook, travel, and experience other cultures. I work hard to apply my belief in the value of a balanced life to my financial counsel. My goal in working is to encourage and enable people to succeed financially so they may lead the best lives possible.

Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.